Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

Blood Cancer Journal, Published online: 04 July 2023; doi:10.1038/s41408-023-00870-2Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

Source: Blood Cancer Journal - July 4, 2023 Category: Hematology Authors: P. J. Hengeveld J. Schilperoord-Vermeulen M. Y. van der Klift J. M. N. Dubois P. M. Kolijn F. G. Kavelaars M. Rijken J. A. Dobber K. Nasserinejad S. Kersting P. E. Westerweel A. P. Kater A. W. Langerak M-D. Levin Source Type: research